Zidovudine (CID 35370) - BioAssay Data Summary for Compound
.
BioActivity Outcomes:
Active(1055)
 
 
Inactive(1107)
 
 
Inconclusive(118)
 
 
Unspecified(1532)
 
 
Top Targets:
7TM GPCR Srx(36)
 
 
 
7TM GPCR Srsx(21)
 
 
 
NR LBD PPAR(16)
 
 
 
Tryp SPc(14)
 
 
 
alkPPc(14)
 
 
BioAssay Types:
Literature(2382)
 
 
 
 
 
Screening(551)
 
 
 
 
Confirmatory(455)
 
 
 
 
 
BioActivity Types:
EC50(630)
 
 
 
 
 
IC50(577)
 
 
 
 
 
Potency(348)
 
 
 
 
 
Ki(9)
 
 
 
 
SAR
Target summary
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 3627    Data Row: 3812   Total Pages: 77   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID103188975]
EC50 4e-06Antiviral activity against Human immunodeficiency virus 1 infected in human C8166 cells assessed as inhibition of virus-induced cytopathic effect [AID610675, Type: Literature]
View
2
[SID103188975]
EC50 4e-06Antiviral activity against Human immunodeficiency virus 1 assessed as inhibition of virus-induced cytopathic effects by cell based assay [AID611912, Type: Literature]
View
3
[SID103188975]
IC50 0.0001Antiviral activity against Human immunodeficiency virus 1 subtype G JV 1083 infected in phytohemagglutinin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay [AID576141, Type: Literature]
View
4
[SID103188975]
IC50 0.0001Antiviral activity against Human immunodeficiency virus 1 subtype O BCF03 infected in phytohemagglutinin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay [AID576144, Type: Literature]
View
5
[SID103188975]
IC50 0.00014Antiviral activity against HIV1 TEKI replication in PBMC at 1 uM [AID257926, Type: Literature]
View
6
[SID103188975]
IC50 0.00018Antiviral activity against HIV1 NL4-3 replication in PBMC at 1 uM [AID257928, Type: Literature]
View
7
[SID103188975]
IC50 0.0002Antiviral activity against Human immunodeficiency virus 2 CDC 310319 infected in phytohemagglutinin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay [AID576145, Type: Literature]
View
8
[SID103188975]
IC50 0.0003Antiviral activity against Human immunodeficiency virus 1 subtype F BR/93/020 infected in phytohemagglutinin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay [AID575960, Type: Literature]
View
9
[SID103188975]
IC50 0.0003Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 1.56 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay [AID576379, Type: Literature]
View
10
[SID103188975]
IC50 0.0003Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 0.78 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay [AID576380, Type: Literature]
View
11
[SID103188975]
IC50 0.0003Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay [AID576388, Type: Literature]
View
12
[SID103188975]
IC50 0.0003Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay [AID576389, Type: Literature]
View
13
[SID103188975]
IC50 0.0003Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 6.25 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA [AID576392, Type: Literature]
View
14
[SID103188975]
EC50 0.00032Concentration of the drug resulting in 50% reduction of the viral cytopathic effect against HIV-1 replication in CEM cells. [AID47640, Type: Literature]
View
15
[SID103188975]
IC50 0.0004Antiviral activity against of Human immunodeficiency virus 1 3B infected in AA5 cells infected with 3.13 uL of virus stock assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay [AID576200, Type: Literature]
View
16
[SID103188975]
IC50 0.0005Antiviral activity against simian immunodeficiency virus 69R infected in phytohemagglutinin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay [AID576148, Type: Literature]
View
17
[SID103188975]
IC50 0.0005Antiviral activity against Human immunodeficiency virus 1 subtype O BCF02 infected in phytohemagglutinin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay [AID576143, Type: Literature]
View
18
[SID103188975]
EC50 0.00053Antiviral activity against HIV1 NL 4-3 expressing wild type reverse transcriptase infected in human PBMC by ELISA [AID548556, Type: Literature]
View
19
[SID103188975]
IC50 0.0007Antiviral activity against Human immunodeficiency virus 1 subtype D UG/92/046 infected in phytohemagglutinin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay [AID575958, Type: Literature]
View
20
[SID103188975]
EC50 0.0007In vitro effective concentration against HIV-1 cytopathic effect in T4 cells [AID208555, Type: Literature]
View
21
[SID103188975]
EC50 0.0007Antiviral activity against HIV1 3B assessed as inhibition of virus-induced cytopathogenicity in MT4 cells after 4 days by MTT assay [AID322392, Type: Literature]
View
22
[SID103188975]
EC50 0.0007Dose required to achieve 50% protection of MT-4 cells from HIV-1(IIIB) induced cytopathogenicity, determined by MIT method. [AID105153, Type: Literature]
View
23
[SID103188975]
EC50 0.00073Antiviral activity against HIV1 LAI replication in human PBMC after 5 days [AID287282, Type: Literature]
View
24
[SID103188975]
EC50 0.0008Antiviral activity against HIV1 in MT4 cells [AID290119, Type: Literature]
View
25
[SID103188975]
IC50 0.0008Antiviral activity against Human immunodeficiency virus 1 subtype A RW/92/016 infected in phytohemagglutinin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay [AID575955, Type: Literature]
View
26
[SID103188975]
IC50 0.0008Antiviral activity against HIV1 NL43 infected din human MT4 cells pre-incubated in presence of compound for 48 hrs followed by TZM cells infection with compound treated virus supernatant by X-gal staining based microsocpy [AID676999, Type: Literature]
View
27
[SID103188975]
EC50 0.00096Antiviral activity against HIV1 JRCSF infected in human PBMC assessed as inhibition of viral p24 antigen production after 7 to 10 days by ELISA [AID559939, Type: Literature]
View
28
[SID103188975]
IC50 0.001Antiviral activity against Human immunodeficiency virus 1 TEKI infected in phytohemagglutinin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay [AID575952, Type: Literature]
View
29
[SID103188975]
IC50 0.001Antiviral activity against Human immunodeficiency virus 1 subtype O BCF01 infected in phytohemagglutinin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay [AID576142, Type: Literature]
View
30
[SID103188975]
IC50 0.001Antiviral activity against Human immunodeficiency virus 2 CDC 310342 infected in phytohemagglutinin and interleukin-2-stimulated PBMC assessed as inhibition of viral Reverse transcriptase by [3H]TTP incorporation assay [AID576146, Type: Literature]
View
31
[SID103188975]
IC50 0.001Antiviral activity against Human immunodeficiency virus 1 3B infected in human H9 cells infected with 12.5 uL of virus stock assessed as expression of p24 antigen after 6 days postinfection by ELISA [AID576391, Type: Literature]
View
32
[SID103188975]
EC50 0.001Antiviral activity against HIV1 3B in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique [AID397589, Type: Literature]
View
33
[SID103188975]
EC50 0.001Antiviral activity against HIV1 RF in human H9 cells assessed as inhibition of virus-induced cytopathic effect by formazan-based conventional colorimetric technique [AID397590, Type: Literature]
View
34
[SID103188975]
IC50 0.001Antiviral activity against ROJO virus strain in PBLs (peripheral blood lymphocytes) [AID154771, Type: Literature]
View
35
[SID103188975]
IC50 0.001Antiviral activity against SLKA virus strain in PBLs (peripheral blood lymphocytes) [AID154772, Type: Literature]
View
36
[SID103188975]
IC50 0.001Antiviral activity against WEJO virus strain in PBLs (peripheral blood lymphocytes) [AID154774, Type: Literature]
View
37
[SID103188975]
IC50 0.001Antiviral activity against subtype isolate A strain in PBLs (peripheral blood lymphocytes) [AID154778, Type: Literature]
View
38
[SID103188975]
IC50 0.001Antiviral activity against subtype isolate O strain in PBLs (peripheral blood lymphocytes) [AID154792, Type: Literature]
View
39
[SID103188975]
EC50 0.001Effective conc. required to achieve 50% inhibition of HIV-1 IIIB multiplication in PBM (peripheral blood mononuclear) cells [AID154932, Type: Literature]
View
40
[SID103188975]
ED50 0.001Effective antiviral dose required to block the spread of HIV-1D34 infection in human peripheral blood mononuclear cells [AID89030, Type: Literature]
View
41
[SID103188975]
ED50 0.001Inhibition of HIV-1 D34 replication in human peripheral blood mononuclear cells. [AID81442, Type: Literature]
View
42
[SID103188975]
EC50 0.001Effective concentration of required to inhibit the replication of HIV-1 BY 50% in CEM cells [AID47139, Type: Literature]
View
43
[SID103188975]
EC50 0.001Effective concentration required for antiviral activity against B(EBV+) cell line of AA5 cells of Human by XTT assay [AID38035, Type: Literature]
View
44
[SID103188975]
ED50 0.001Antiviral activity against HIV [AID617754, Type: Literature]
View
45
[SID103188975]
EC50 0.0012The compound was tested for antiviral activity against AZT sensitive strain 9F HIV in PBM cells. [AID152624, Type: Literature]
View
46
[SID103188975]
EC50 0.0012Antiviral activity against HIV1 subtype A isolate 92UG029 infected in human MDM after 48 to 72 hrs by MTS assay [AID548544, Type: Literature]
View
47
[SID103188975]
EC50 0.0012Antiviral activity against HIV1 subtype B-3B infected in 1 hr-pretreated human MT2 cells assessed as inhibition of multicycle replication measured on day 5 postinfection by RT SPA [AID519861, Type: Literature]
View
48
[SID103188975]
EC50 0.0013Antiviral activity against HIV1 subtype A isolate 92UG037 infected in human MDM after 48 to 72 hrs by MTS assay [AID548545, Type: Literature]
View
49
[SID103188975]
EC50 0.0014Concentration required to inhibit replication of HIV-1 HTLV-IIIB strain in PBL (peripheral blood lymphocytes) cells [AID154769, Type: Literature]
View
50
[SID103188975]
IC50 0.0015Effective concentration required to achieve 50% protection of MT-4 cells against the cytopathic effect of HIV-1. [AID106037, Type: Literature]
View